Trenbolone Bloodwork: 8 Markers to Monitor and Red Lines to Stop

Trenbolone is the most potent anabolic-androgenic steroid in common use. It is also the one that generates the most bloodwork confusion, the most misinterpreted results, and the most avoidable harm. Most users running tren order a standard steroid panel, see wildly abnormal numbers, and either panic or ignore them, sometimes both at the same time.

The problem is that a standard steroid panel was not designed for tren. It misses compound-specific traps: falsely elevated estradiol on immunoassays, creatinine that hides kidney damage, prolactin that climbs silently for six weeks before symptoms appear, and haematocrit that rises faster than on any other compound because the estradiol brake on erythropoiesis is gone.

This guide covers the eight markers that matter specifically on trenbolone, the thresholds that require action, and the hard-stop red lines that mean the cycle ends today. If you have not read a general bloodwork guide first, start with the complete bloodwork guide for bodybuilders and come back here.

Why trenbolone needs its own bloodwork protocol

Trenbolone's pharmacology is fundamentally different from testosterone and most other anabolic steroids. The mechanisms matter here: they explain which markers to test, which assays to use, and why the numbers often look wrong even when they are not.

Trenbolone acetate and trenbolone enanthate share the same active compound: 17beta-hydroxyestra-4,9,11-trien-3-one. The 4,9,11-triene structure, three double bonds in the steroid backbone, confers several properties that distinguish tren from testosterone:

No aromatization. Trenbolone cannot be converted to estradiol by aromatase. This sounds like a benefit, and in terms of water retention and gynecomastia prevention, it partially is. But estradiol serves critical physiological functions: it protects HDL cholesterol, blunts erythropoiesis, and supports libido. Running tren without co-administered aromatizing androgens means losing these protective effects entirely.

Strong androgenic potency. Trenbolone's binding affinity for the androgen receptor (AR) is comparable to dihydrotestosterone (DHT), making it one of the most potent AR agonists among commonly used AAS (Bauer et al., 2000). At the cellular level, this drives more aggressive erythropoiesis, more pronounced androgenic side effects, and more severe lipid disruption than equivalent doses of testosterone.

Progestogenic activity. Trenbolone has significant affinity for the progesterone receptor, higher than progesterone itself in some assays (Bauer et al., 2000). This progestogenic activity contributes to prolactin elevation through mechanisms that differ from dopamine suppression alone, and it is why standard anti-prolactin frameworks designed for dopaminergic agents require adjustment on tren.

Unique metabolite profile. Trenbolone produces metabolites with a 4,9,11-triene chromophore that absorb visible light, giving urine a characteristic yellow-orange colour (Putz et al., 2020). Twenty distinct metabolites have been identified in human urine. Several of these metabolites cross-react with immunoassay antibodies designed to detect estradiol, creating the false estradiol problem discussed in detail below.

Nephrotoxicity. Trenbolone's metabolite burden on the kidneys is higher than most AAS. High androgenic activity, progestogenic receptor activation, and structurally novel metabolites all contribute to glomerular injury that creatinine-based monitoring consistently misses.

The upshot: tren needs testing for markers that standard steroid panels ignore, using assay methods that most default panels do not specify.

The false estradiol problem: immunoassay vs LC-MS/MS

Click to expand

This is the most important technical point in this entire article. Get it wrong and you will either over-aromatize yourself into bone density loss, or crash your estradiol with unnecessary anastrozole.

Standard estradiol blood tests use immunoassay technology: an antibody is raised against estradiol, the patient's blood sample competes with a labelled estradiol analogue for that antibody, and the signal intensity tells you how much estradiol is present. The fundamental assumption is that the antibody only binds estradiol. On trenbolone, that assumption fails.

How immunoassay antibodies cross-react with tren metabolites

Immunoassay antibodies cannot perfectly distinguish between steroid molecules with similar structures, especially when competing steroids are present at high concentrations. Trenbolone metabolites, particularly those with the 4,9,11-triene structure, are structurally similar enough to estradiol that they compete for the immunoassay antibody, producing a falsely elevated result.

This problem is not unique to tren. A landmark analysis by Stanczyk et al. found that immunoassays "can substantially overestimate E2 levels" due to cross-reactivity, particularly in populations where unusual steroids are present (Stanczyk et al., 2010). Ketha et al. demonstrated overestimation "by up to several fold" compared to mass spectrometry reference methods (Ketha et al., 2014). Handelsman et al. found that 57% of E2 calibrators deviated significantly from their stated values across commercial immunoassay platforms (Handelsman et al., 2023).

In 2018, Grimstad et al. showed that 94% of US clinical laboratories use immunoassay for routine estradiol testing (Grimstad et al., 2018). A 2025 study by Giralt et al. demonstrated that exemestane, a 19-nor steroidal aromatase inhibitor with structural similarities to tren metabolites, produced falsely elevated estradiol readings on immunoassay, a finding directly relevant to trenbolone users (Giralt et al., 2025).

The phantom high E2 scenario

Here is what this looks like in practice. A tren user orders a standard hormone panel. The lab returns an estradiol of 120 pg/mL, far above the typical male reference range of 10-40 pg/mL. The user assumes he is over-aromatizing, starts anastrozole, and within two weeks has crashed his actual estradiol to near zero. He then experiences joint pain, severe libido loss, depression, and potentially worse cardiovascular risk. His actual estradiol was probably normal the entire time. The immunoassay was reading trenbolone metabolites, not estradiol.

The reverse also happens: a tren user with genuinely suppressed estradiol from a co-aromatase inhibitor sees a "normal" immunoassay result because tren metabolites are inflating the number, and never recognises the deficiency.

Which test to order

Request "Estradiol, Sensitive (LC/MS/MS)" by name when ordering your panel. This test uses liquid chromatography-tandem mass spectrometry, which separates molecules by mass before measuring them. Tren metabolites have different masses than estradiol and are excluded from the measurement. The result is an accurate estradiol reading regardless of what other steroids are circulating.

In Australia, LabCorp-affiliated and some private pathology services offer the sensitive LC-MS/MS assay. Request it explicitly; the default when your GP orders "estradiol" will be immunoassay. The cost difference is usually minor. For a deeper discussion of estradiol interpretation, see our article on estradiol on TRT, which covers reference ranges and management in detail.

Prolactin: the 19-nor marker nobody manages properly

Every 19-nor steroid, nandrolone, trenbolone, can elevate prolactin. Trenbolone's progestogenic activity makes it particularly potent in this regard. Yet most tren users either ignore prolactin entirely or manage it with P5P (pyridoxal-5-phosphate) based on gym lore rather than evidence.

Why prolactin rises on tren

Prolactin secretion from pituitary lactotroph cells is tonically inhibited by dopamine. Many drugs elevate prolactin by blocking dopamine receptors. Trenbolone's mechanism is different and more complex: its progestogenic activity modulates lactotroph function through progesterone receptors (Camilletti et al., 2019), which means dopamine-centric treatments may be less effective than expected, and the elevation can be harder to predict.

In practice, prolactin typically peaks between weeks 4 and 8 on tren, with users who are sensitive seeing values 2-3x the upper limit of normal (ULN). Symptoms of hyperprolactinemia include nipple sensitivity, lactation (galactorrhea), reduced libido, anorgasmia, and emotional blunting. Some users experience significant prolactin elevation without any symptoms; others develop symptoms at only modestly elevated levels.

P5P vs cabergoline: what the evidence actually says

The bodybuilding community has long championed P5P (the active form of vitamin B6) as a prolactin management tool on cycle. The evidence does not support this practice.

The primary citation for P5P in prolactin management is a 1979 study by Brambilla et al. that specifically tested pyridoxine (B6) for drug-induced hyperprolactinemia (Brambilla et al., 1979). The result: pyridoxine completely failed to reduce prolactin in drug-induced hyperprolactinemia. The finding that B6 can influence prolactin comes from studies in physiological ranges and specific hormonal conditions, not drug-induced elevations. Running P5P as your only anti-prolactin strategy on tren means running no anti-prolactin strategy.

Cabergoline is the appropriate intervention. It is a potent, selective dopamine D2 receptor agonist with strong evidence for prolactin reduction. A 2024 position statement from Brazilian endocrinology societies reports 80-90% efficacy for prolactin normalization with dopamine agonists (Benetti-Pinto et al., 2024). A 2025 prospective study by Nepal et al. found 97% prolactin normalization at 6 months with cabergoline as first-line therapy (Nepal et al., 2025).

The standard starting dose in the medical literature is 0.25 mg twice weekly, titrated up based on prolactin response. In the context of tren use, many athletes use 0.25-0.5 mg twice weekly proactively. Whether to use cabergoline prophylactically or threshold-based depends on your prolactin history and the dose of tren.

When to test prolactin on tren

A practical threshold-based framework:

• Baseline before starting the cycle.
• Week 4-6 retest: this is the peak elevation window for most 19-nor users.
• Any time symptoms develop, regardless of where you are in the cycle.

Management thresholds:

• Asymptomatic prolactin below 1.5x ULN: monitor and retest.
• Asymptomatic prolactin 1.5-2x ULN: consider starting cabergoline at 0.25 mg twice weekly.
• Symptomatic prolactin at any level, or asymptomatic prolactin above 2x ULN: start cabergoline.
• Prolactin above 3x ULN: start cabergoline and reduce tren dose.
• Prolactin above 3x ULN with galactorrhea: hard stop.

Prolactin should be on every tren panel from week 4 onwards. It is one of the most manageable risks on cycle if caught early, and one of the most disruptive to quality of life if ignored.

Kidney markers: why creatinine lies and cystatin C tells the truth

Trenbolone's impact on the kidneys is underappreciated and systematically underdetected by standard kidney function tests. Understanding why creatinine is the wrong marker on tren, and what to order instead, could prevent permanent kidney damage.

The creatinine problem on cycle

Creatinine is produced by muscle metabolism of creatine. Because trenbolone significantly increases muscle mass and creatine turnover, serum creatinine rises from muscle production alone, independent of any change in actual kidney filtering function. This inflates creatinine while the estimated GFR (eGFR) calculated from creatinine falls, suggesting worse kidney function than actually exists. Standard creatinine-based eGFR (eGFRcr) in bodybuilders consistently underestimates true kidney function due to this muscle mass confound.

The critical finding comes from Ozkurt et al. (2023), who studied 12 AAS-using bodybuilders and 12 supplement-only controls. eGFRcr was identical between groups. But eGFR calculated from cystatin C (eGFRcys) was significantly lower in AAS users (p=0.039), and albumin-to-creatinine ratio (ACR) was significantly elevated (p < 0.001) (Ozkurt et al., 2023). The study confirmed what nephrology researchers have suspected: creatinine-based kidney assessment in bodybuilders systematically misses real glomerular injury.

Cystatin C: the marker that catches what creatinine misses

Cystatin C is a small protein filtered by the glomerulus but produced at a constant rate by all nucleated cells regardless of muscle mass. It is not affected by diet, exercise, or muscle hypertrophy. This makes it an ideal kidney marker for athletes on AAS, where creatinine is confounded by multiple factors.

When glomerular filtration rate falls due to kidney injury, cystatin C accumulates in the blood. This elevation appears before creatinine-based markers change significantly, and it is not masked by increased creatinine production from muscle. In the context of tren use, cystatin C can detect glomerular injury while creatinine still looks normal.

The landmark Herlitz et al. (2010) study found that 10 bodybuilders who had used AAS for over five years all showed focal segmental glomerulosclerosis (FSGS) on kidney biopsy. Mean proteinuria was 10.1 g/day, 30% had nephrotic syndrome, and one had dialysis-dependent kidney failure (Herlitz et al., 2010). These are permanent, irreversible outcomes. FSGS does not resolve. Catching glomerular injury early, while it is still reversible, requires testing that creatinine cannot provide.

For the full picture on cystatin C interpretation and reference ranges, see our dedicated article on cystatin C and kidney health for bodybuilders.

ACR: the early warning for proteinuria

Albumin-to-creatinine ratio (ACR) on a spot urine sample measures how much albumin is leaking into the urine, a direct marker of glomerular membrane damage. Normal ACR is below 3 mg/mmol. Microalbuminuria is 3-30 mg/mmol. Overt proteinuria is above 30 mg/mmol.

A rising ACR on cycle is the earliest warning sign of FSGS-type injury. The glomerular basement membrane is being damaged, and albumin is leaking through before creatinine has changed, before cystatin C has moved significantly, and long before any symptoms appear. Include ACR on every tren cycle panel.

The orange urine question

Many tren users notice orange or rust-coloured urine, particularly with trenbolone acetate at higher doses. This is caused by trenbolone metabolites, specifically 17-epitrenbolone glucuronide and related compounds, which have a yellow-orange chromophore from the 4,9,11-triene structure (Putz et al., 2020).

This is not haematuria. A dipstick urine test on orange tren urine will be negative for blood. Microscopy shows no red blood cells. The colour is purely from chromophoric metabolites.

If your dipstick IS positive for blood, that is not the trenbolone orange urine phenomenon. That is haematuria, which requires investigation. A positive dipstick with microscopic confirmation of red blood cells in urine is a hard-stop indicator. The distinction matters: orange urine without dipstick-positive haematuria is cosmetic; dipstick-positive haematuria during a tren cycle is a kidney red line.

Lipids: how tren crashes HDL to single digits

Click to expand

Trenbolone produces some of the most severe HDL suppression of any AAS. Knowing why matters, because it explains why no supplement adequately prevents it, and why cycle length matters more than any intervention.

The hepatic lipase mechanism

All androgens with significant androgenic potency increase the activity of hepatic lipase (HL), an enzyme that breaks down HDL particles (Bausserman et al., 1997). The result is accelerated HDL catabolism: HDL levels fall, often dramatically. Trenbolone's high androgen receptor affinity makes it one of the most potent HL stimulators among commonly used AAS.

In a study of stanozolol, a compound with comparable androgenic potency characteristics, HL activity increased by 277% and HDL cholesterol fell by 49% (Bausserman et al., 1997). Tren users regularly report HDL values in the single digits in mg/dL (4, 5, 6 mg/dL, equivalent to roughly 0.1-0.15 mmol/L). Even values of 10-15 mg/dL (0.25-0.4 mmol/L) represent severe suppression.

The cardiovascular implications are serious. Souza et al. (2019) found coronary artery plaques in 25% of young AAS users on CT angiography, with zero plaques in matched non-users. HDL efflux capacity, a functional measure of HDL's ability to remove cholesterol from arterial walls, was just 20% in AAS users compared to 23-24% in non-users (Souza et al., 2019). This is not a theoretical risk. It is measurable coronary atherosclerosis in athletes in their 20s and 30s.

What total cholesterol hides

Here is the deceptive part: total cholesterol can look normal or even low while HDL is critically suppressed. A total cholesterol of 4.5 mmol/L sounds reassuring. If HDL is 0.5 mmol/L, that gives a total-to-HDL ratio of 9:1, a catastrophically elevated cardiovascular risk indicator. Always look at the ratio, not just total cholesterol.

LDL typically rises on tren through reduced LDL receptor expression and increased VLDL production. Triglycerides usually increase as well. The net lipid picture on a tren cycle looks like someone with severe metabolic syndrome, which, at the vascular level, it functionally is.

Adding oral AAS compounds, particularly stanozolol (Winstrol) or oxymetholone (Anadrol), to a tren stack makes the lipid picture dramatically worse. If you choose to run a tren cycle, stack orals with caution and accept that each additional compound compounds the HDL destruction.

Timeline for HDL recovery

The reassuring part: HDL damage from AAS is largely reversible. Garevik et al. (2011) showed HDL normalises within approximately six months of AAS cessation in most users (Garevik et al., 2011). The key word is cessation. Continuing tren indefinitely means continuously suppressed HDL and continuously accelerated atherogenesis. Limiting cycle length to 10-12 weeks limits cumulative exposure to the period of worst lipid profile.

For a full discussion of lipid management strategies, see our article on cholesterol on steroids.

Haematocrit: the tren erythropoiesis paradox

Trenbolone produces faster, more severe haematocrit elevation than most other AAS, and the reason is mechanistically important: tren removes the estradiol brake on erythropoiesis.

How androgens drive red cell production

Testosterone stimulates red blood cell production through two established mechanisms. First, it directly stimulates the kidney to produce erythropoietin (EPO), the primary driver of red cell production (Bachman et al., 2014). Second, it suppresses hepcidin, the hormone that limits iron absorption, freeing more iron for haemoglobin synthesis (Bachman et al., 2014). The molecular mechanism in mouse models involves androgen receptor activation in peritubular myoid cells and Sertoli-like kidney cells to upregulate EPO gene expression (Guo et al., 2013).

The counter-regulatory brake comes from estradiol. Gonzales et al. (2025) demonstrated that estradiol counteracts androgen-driven erythropoiesis through GATA1, a key transcription factor in red cell development, and that a high testosterone-to-estradiol ratio correlates with excessive erythrocytosis (Gonzales et al., 2025).

Trenbolone does not aromatize. Running tren means running a compound with potent androgenic drive on erythropoiesis and no estradiol counter-regulation. The testosterone-to-estradiol ratio is, effectively, infinite on the erythropoietic axis. This is why tren-plus-testosterone stacks elevate haematocrit faster than testosterone alone: the tren adds androgenic erythropoietic drive while contributing zero aromatizable substrate to restrain it.

Hard-stop haematocrit thresholds

Haematocrit above 54% is the established threshold for intervention in TRT guidelines, and it is the threshold that applies on tren cycle as well. The risk above this level is hyperviscosity: blood thick enough to impair microvascular flow, increase clot formation, and elevate stroke risk.

Practical framework for haematocrit management on tren:

• Below 50%: monitor. Retest at weeks 4 and 8.
• 50-52%: caution zone. Retest in two weeks. Ensure adequate hydration.
• 52-54%: consider therapeutic phlebotomy or blood donation. Reduce compound dose.
• Above 54%: hard stop. Do not wait for symptoms. Donate blood or pursue therapeutic phlebotomy immediately.

One important caveat from Bond et al. (2024): repeated phlebotomy depletes iron stores, and severe iron depletion may paradoxically increase thrombotic risk through mechanisms involving platelet reactivity and small-cell production (Bond et al., 2024). Monitor ferritin alongside haematocrit. Ferritin below 30 mcg/L alongside elevated haematocrit suggests iron-depleted erythropoiesis, which needs more careful management than simple phlebotomy.

For full haematocrit management options, see our articles on haemoglobin and haematocrit on TRT and how to lower haematocrit. For the full haematology panel context, including red cell indices, reticulocytes, and platelet markers, see our guide on the haematology panel for enhanced athletes.

Thyroid: why your T3 looks low on tren

Many tren users notice that their thyroid panel looks off on cycle, specifically low total T3 and T4. Before assuming hypothyroidism and reaching for T3 supplementation, understand the mechanism.

Androgens suppress thyroid-binding globulin

The explanation is not that tren is damaging your thyroid. It is that androgens suppress the liver's production of thyroid-binding globulin (TBG), the protein that carries most thyroid hormones in the bloodstream (Small et al., 1984). With less TBG available, total T4 and total T3 fall because more hormone is circulating in the free (unbound) form and less is bound and "stored" in the protein-bound pool.

This was confirmed in controlled studies. Deyssig et al. (1993) showed that AAS reduced TBG and total T4/T3, but free T4 and TSH remained unchanged (Deyssig et al., 1993). Alen et al. (1987) found TSH, T4, T3, and TBG all decreased in AAS users, with the critical observation that free thyroid hormone levels did not fall proportionally (Alen et al., 1987).

The test that matters

TSH (thyroid-stimulating hormone) is your reliable screening marker for thyroid function on cycle. If TSH is normal (roughly 0.5-4.5 mIU/L), you are not hypothyroid regardless of how low your total T3 looks. The pituitary is not sensing a deficit of free thyroid hormone, because there is none. Low total T3 with normal TSH and normal free T4 is a TBG suppression pattern, not hypothyroidism.

Adding exogenous T3 to a tren cycle based on suppressed total T3 is a mistake. You would be adding T3 in the context of already adequate free thyroid hormone, risking thyrotoxicosis and permanent thyroid suppression. Test free T3 and free T4 if you want to confirm thyroid status beyond TSH alone. For a full explanation of thyroid marker interpretation on AAS, see our article on thyroid function on steroids.

Liver enzymes: separating tren from training

The liver enzyme picture on tren is more complicated than most online resources admit. Trenbolone has long been described as "not hepatotoxic" because it is injectable and 17-beta reduced rather than 17-alpha alkylated. That framing is too clean.

AST and ALT from muscle, not liver

AST and ALT will be elevated on any AAS cycle, and this elevation is largely driven by muscle damage from training, not liver injury. Both enzymes are present in muscle tissue. Heavy resistance training with supraphysiological androgens produces AST/ALT elevations of 2-5x the upper limit of normal that have no diagnostic significance for liver pathology.

Pertusi et al. (2001) found that 63% of physicians incorrectly diagnosed liver disease in strength athletes based on elevated AST/ALT without recognising the muscle origin (Pertusi et al., 2001). The enzyme that discriminates liver from muscle origin is GGT (gamma-glutamyl transferase). GGT is expressed in the liver but not in muscle. When AST/ALT are elevated but GGT is normal, the source is muscle. When GGT rises alongside AST/ALT, the liver is involved.

GGT as the discriminator

Dickerman et al. (1999) confirmed this in a study of exercising AAS users: GGT was normal in all exercising groups regardless of AAS use. Only patients with hepatitis showed GGT elevation. The conclusion: GGT is a specific hepatic marker unaffected by exercise and unaffected by standard AAS use in most contexts (Dickerman et al., 1999).

"Most contexts" is the important qualifier. Trenbolone is not hepatically inert. Boks et al. (2017) published a case report of biopsy-confirmed cholestatic hepatitis from injectable trenbolone enanthate, with marked GGT elevation and resolution after cessation (Boks et al., 2017). This is a rare outcome, but it demonstrates that injectable tren can, in some individuals, cause genuine hepatic injury. Monitor GGT specifically. If GGT rises above 3x ULN alongside elevated AST/ALT, this is a liver signal, not a muscle signal.

For the full framework on interpreting liver enzymes during AAS use, see our article on liver enzymes on steroids.

The complete tren monitoring timeline

Click to expand

Here is a practical schedule for bloodwork across a standard 10-12 week tren cycle:

One practical note: if your cycle uses trenbolone acetate (shorter ester, faster onset), push the week 4 prolactin test to week 3. Acetate reaches steady-state faster than enanthate and prolactin can peak earlier.

Red lines: when to drop tren immediately

These are not caution signals or reasons to reduce dose. These are the thresholds at which the cycle ends that day, dose goes to zero, and you seek medical assessment.

Haematocrit above 54%. Blood viscosity at this level carries meaningful stroke, pulmonary embolism, and MI risk. Stop all erythropoietic compounds and pursue phlebotomy.

ACR above 30 mg/mmol (overt proteinuria). This level of albumin leakage indicates established glomerular injury. Continuing tren at this point risks progression toward FSGS-type nephropathy that may not fully reverse.

Cystatin C eGFR below 60 ml/min/1.73m2. This represents stage 3a chronic kidney disease on the CKD classification system. In a bodybuilder, this is a serious red line requiring investigation and cessation.

Creatinine rising more than 30% above your personal baseline. Even accounting for the muscle mass confound, a 30%+ rise in creatinine above your pre-cycle baseline is a concerning signal.

GGT above 3x ULN with concurrent AST/ALT elevation. This pattern indicates genuine hepatic injury, not exercise-related enzyme release.

Clinical jaundice. Yellow skin or sclera (whites of eyes) indicates severe hepatic compromise. Emergency presentation is appropriate.

Prolactin above 2x ULN with galactorrhea, severe erectile dysfunction, or inability to orgasm. Symptomatic hyperprolactinemia at this level warrants cessation and medical evaluation, not just cabergoline initiation.

Dipstick-positive haematuria confirmed on repeat testing. This is not the orange tren urine; this is blood in urine indicating kidney or urinary tract pathology.

Persistent headache with facial flushing and visual changes. This triad may indicate hyperviscosity syndrome from excessive haematocrit. It is a vascular emergency.

Key takeaways

• Order LC-MS/MS estradiol specifically on tren. Standard immunoassay gives falsely elevated results due to cross-reactivity with tren metabolites.
• Test prolactin at baseline and week 4-6. Manage with cabergoline, not P5P. P5P failed in controlled studies for drug-induced hyperprolactinemia.
• Use cystatin C and ACR for kidney monitoring, not creatinine alone. Creatinine is confounded by muscle mass and will miss early glomerular injury.
• Orange urine from tren metabolites is not haematuria. Dipstick-positive haematuria is a red line; orange urine with negative dipstick is not.
• HDL will crash on tren. No supplement fully prevents this. Limit cycle length to limit cumulative cardiovascular exposure.
• Haematocrit rises faster on tren because there is no estradiol to brake erythropoiesis. Monitor from week 4. Hard stop at 54%.
• Low total T3 on cycle is a TBG suppression artifact, not hypothyroidism. Check TSH. Normal TSH means no thyroid deficit regardless of total T3.
• Monitor GGT specifically for liver assessment. AST/ALT elevated with normal GGT is muscle, not liver. GGT above 3x ULN with concurrent AST/ALT elevation is a liver signal.
• Know your red lines before you start. Have a plan for what to do if haematocrit crosses 54% or ACR rises. Reactive decisions made in the middle of a cycle are worse than pre-established stop criteria.

---

References

Alen, M., Rahkila, P., Reinila, M., & Vihko, R. (1987). Androgenic-anabolic steroid effects on serum thyroid, pituitary and steroid hormones in athletes. American Journal of Sports Medicine, 15(4), 357-361. PMID: 3661817

Bachman, E., Travison, T. G., Basaria, S., Davda, M. N., Guo, W., Li, M., ... & Bhasin, S. (2014). Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin. Journals of Gerontology Series A, 69(6), 725-735. PMID: 24158761

Bauer, E. R., Daxenberger, A., Petri, T., Sauerwein, H., & Meyer, H. H. (2000). Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. APMIS, 108(12), 838-846. PMID: 11252818

Bausserman, L. L., Saritelli, A. L., & Herbert, P. N. (1997). Effects of short-term stanozolol administration on serum lipoproteins in hepatic lipase deficiency. Metabolism, 46(9), 992-996. PMID: 9284885

Benetti-Pinto, C. L., Prestes Nacul, A., Rosa-E-Silva, J. C., & Maciel, G. A. R. (2024). Treatment of hyperprolactinemia in women: a position statement. Archives of Endocrinology and Metabolism, 68, e230504. PMID: 38578473

Boks, M. N., Tiebosch, A. T., & van der Waaij, L. A. (2017). A jaundiced bodybuilder: Cholestatic hepatitis as side effect of injectable anabolic-androgenic steroids. Journal of Sports Science, 5(1), 9-12. PMID: 27937337

Bond, P., Verdegaal, T., & Smit, D. L. (2024). Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocrine Connections, 13(10), e240283. PMID: 39212549

Brambilla, G., Guidugli, F., & Formento, M. (1979). Failure of pyridoxine to reduce drug-induced hyperprolactinemia. Clinical Pharmacology and Therapeutics, 26(4), 403-407. PMID: 43342

Camilletti, M. A., Abeledo-Machado, A., Faraoni, E. Y., & Thomas, P. (2019). New insights into progesterone actions on prolactin secretion and prolactinoma development. Steroids, 152, 108496. PMID: 31521709

Deyssig, R., & Weissel, M. (1993). Ingestion of androgenic-anabolic steroids induces mild thyroidal impairment in male body builders. Journal of Clinical Endocrinology and Metabolism, 76(4), 1069-1071. PMID: 8473383

Dickerman, R. D., Pertusi, R. M., Zachariah, N. Y., Dufour, D. R., & McConathy, W. J. (1999). Anabolic steroid-induced hepatotoxicity: is it overstated? Clinical Journal of Sport Medicine, 9(1), 34-39. PMID: 10336050

Garevik, N., Strahm, E., Garle, M., Lundmark, J., Stahle, L., Ekstrom, L., & Wikstrand, A. H. (2011). Long term perturbation of endocrine parameters and cholesterol metabolism after discontinued abuse of anabolic androgenic steroids. Journal of Steroid Biochemistry and Molecular Biology, 127(3-5), 295-300. PMID: 21884791

Giralt, M., Salinas, I., Simo-Servat, O., Palomino, L., & Puig-Domingo, M. (2025). Falsely elevated serum estradiol due to exemestane interference in immunoassay. Endocrinology, Diabetes and Nutrition, 72(3), 101-104. PMID: 40114653

Gonzales, G. F. (2025). Monge's disease at 100 years: Revisiting the origins and endocrine mechanisms of chronic mountain sickness. Science Progress, 108(4), 368504251387827. PMID: 41118472

Grimstad, F. W., Le, B., Zganjar, A., & Flores, J. E. (2018). An evaluation of reported follicle-stimulating hormone, luteinizing hormone, estradiol, and prolactin reference ranges in the United States. Urology, 120, 114-119. PMID: 30056193

Guo, W., Bachman, E., Li, M., Roy, C. N., Blusztajn, J., Bellucci, A., & Bhasin, S. (2013). Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell, 12(2), 280-291. PMID: 23399021

Handelsman, D. J., Jones, G. R. D., Kouzios, D., & Desai, R. (2023). Evaluation of testosterone, estradiol and progesterone immunoassay calibrators by liquid chromatography mass spectrometry. Clinical Chemistry and Laboratory Medicine, 61(9), 1612-1618. PMID: 37272075

Herlitz, L. C., Markowitz, G. S., Farris, A. B., Schwimmer, J. A., Stokes, M. B., Kunis, C., Colvin, R. B., & D'Agati, V. D. (2010). Development of focal segmental glomerulosclerosis after anabolic steroid abuse. Journal of the American Society of Nephrology, 21(1), 163-172. PMID: 19917783

Ketha, H., Kaur, S., & Singh, R. J. (2014). Clinical applications of LC-MS sex steroid assays: evolution of methodologies in the 21st century. Current Opinion in Endocrinology, Diabetes and Obesity, 21(3), 217-226. PMID: 24739314

Nepal, M., Bajracharya, A., Karki, S., & Adhikari, S. (2025). Study of clinical profile and early response to dopamine agonist therapy in patients of hyperprolactinemia. Indian Journal of Endocrinology and Metabolism, 29(6), 667-673. PMID: 41497301

Ozkurt, S., Ozakin, E., Gungor, H., & Yalcin, A. U. (2023). Assessment of renal function of bodybuilders using anabolic androgenic steroids and diet supplements. Cureus, 15(8), e43058. PMID: 37680426

Pertusi, R., Dickerman, R. D., & McConathy, W. J. (2001). Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids: hepatitis or rhabdomyolysis? Journal of the American Osteopathic Association, 101(7), 391-394. PMID: 11476029

Putz, M., Enev, V., Gauw, S., Guddat, S., Wachsmuth, C., Thomas, A., & Thevis, M. (2020). Identification and characterization of trenbolone metabolites produced by in vitro biotransformation and their significance for doping controls. Drug Testing and Analysis, 12(9), 1358-1369. PMID: 32509736

Small, M., Beastall, G. H., Semple, C. G., Cowan, R. A., & Forbes, C. D. (1984). Alteration of hormone levels in normal males given the anabolic steroid stanozolol. Clinical Endocrinology, 21(1), 49-55. PMID: 6430603

Souza, F. R., Dos Santos, M. R., Porello, R. A., Favero, F. M., Bento, L. C., Lima, S. T., Serrano, C. V., Negrao, C. E., Salemi, V. M. C., & Kalil, R. A. K. (2019). Diminished cholesterol efflux mediated by HDL and coronary artery disease in male anabolic steroid users. Atherosclerosis, 283, 100-105. PMID: 30826541

Stanczyk, F. Z., Jurow, J., & Hsing, A. W. (2010). Limitations of direct immunoassays for measuring circulating estradiol levels in postmenopausal women and men in epidemiologic studies. Cancer Epidemiology, Biomarkers and Prevention, 19(4), 903-906. PMID: 20332268